• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

存在中和抗体时的新冠病毒再感染情况。

COVID-19 reinfection in the presence of neutralizing antibodies.

作者信息

Zhang Ju, Ding Nan, Ren Lili, Song Rui, Chen Danying, Zhao Xuesen, Chen Budong, Han Junyan, Li Jiarui, Song Yangzi, Di Lin, Han Kai, Yu Fengting, Xie Ruming, Chen Zhihai, Xie Wen, Liu Jingyuan, Cen Shan, Bi Yuhai, Wu Angela R, Zhang Fujie, Chen Chen, Zeng Hui

机构信息

Beijing Ditan Hospital, Capital Medical University, China.

NHC Key Laboratory of Systems Biology of Pathogens and Christophe Mérieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, China.

出版信息

Natl Sci Rev. 2021 Jan 11;8(4):nwab006. doi: 10.1093/nsr/nwab006. eCollection 2021 Apr.

DOI:10.1093/nsr/nwab006
PMID:34676097
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7928639/
Abstract

After a short recovery period, COVID-19 reinfections could occur in convalescent patients, even those with measurable levels of neutralizing antibodies. Effective vaccinations and protective public health measures are recommended for the convalescent COVID-19 patients.

摘要

经过短暂的恢复期后,新冠康复患者可能会再次感染新冠病毒,即使是那些体内有可检测水平中和抗体的患者。建议对新冠康复患者进行有效的疫苗接种和采取保护性公共卫生措施。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9f8/8294352/c2eae3c2c958/nwab006fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9f8/8294352/c2eae3c2c958/nwab006fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9f8/8294352/c2eae3c2c958/nwab006fig1.jpg

相似文献

1
COVID-19 reinfection in the presence of neutralizing antibodies.存在中和抗体时的新冠病毒再感染情况。
Natl Sci Rev. 2021 Jan 11;8(4):nwab006. doi: 10.1093/nsr/nwab006. eCollection 2021 Apr.
2
[Prediction of protection probability against Omicron BA.1, BA.4 and BA.5 variants in symptomatic infections with prototype strain based on neutralization antibody levels].[基于中和抗体水平预测原型株有症状感染中针对奥密克戎BA.1、BA.4和BA.5变异株的保护概率]
Zhonghua Yi Xue Za Zhi. 2023 May 16;103(18):1429-1434. doi: 10.3760/cma.j.cn112137-20221221-02685.
3
Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies.轻度 SARS-CoV-2 感染与再感染无关,并提供持久的刺突、核衣壳和病毒中和抗体。
Microbiol Spectr. 2021 Oct 31;9(2):e0008721. doi: 10.1128/Spectrum.00087-21. Epub 2021 Sep 1.
4
Neutralizing Antibodies against SARS-CoV-2: Importance of Comorbidities in Health Personnel against Reinfections.针对 SARS-CoV-2 的中和抗体:合并症对卫生人员再感染的重要性。
Viruses. 2023 Nov 30;15(12):2354. doi: 10.3390/v15122354.
5
Immunologic memory to SARS-CoV-2 in convalescent COVID-19 patients at 1 year postinfection.感染后 1 年的 COVID-19 恢复期患者对 SARS-CoV-2 的免疫记忆。
J Allergy Clin Immunol. 2021 Dec;148(6):1481-1492.e2. doi: 10.1016/j.jaci.2021.09.008. Epub 2021 Sep 15.
6
Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.新型冠状病毒感染后长达13个月的抗体反应演变及再次感染风险。
EBioMedicine. 2021 Sep;71:103561. doi: 10.1016/j.ebiom.2021.103561. Epub 2021 Aug 27.
7
Predictors of reinfection with pre-Omicron and Omicron variants of concern among individuals who recovered from COVID-19 in the first year of the pandemic.大流行第一年从 COVID-19 中康复的个体中与预奥密克戎和奥密克戎变异株再感染相关的预测因素。
Int J Infect Dis. 2023 Jul;132:72-79. doi: 10.1016/j.ijid.2023.04.395. Epub 2023 Apr 16.
8
SARS-CoV-2 Reinfections in Health-Care Workers, 1 March 2020-31 January 2023.2020 年 3 月 1 日至 2023 年 1 月 31 日期间医护人员中 SARS-CoV-2 再感染情况。
Viruses. 2023 Jul 14;15(7):1551. doi: 10.3390/v15071551.
9
Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England.自然感染后新型 SARS-CoV-2 变体再感染:英国 13 家养老院的前瞻性观察队列研究。
Lancet Healthy Longev. 2021 Dec;2(12):e811-e819. doi: 10.1016/S2666-7568(21)00253-1. Epub 2021 Dec 1.
10
SARS-CoV-2 Reinfection in a Healthcare Worker Despite the Presence of Detectable Neutralizing Antibodies.SARS-CoV-2 再感染,尽管存在可检测的中和抗体。
Viruses. 2021 Apr 12;13(4):661. doi: 10.3390/v13040661.

引用本文的文献

1
Impact of maternal COVID-19 infection on offspring immunity and maternal-fetal outcomes at different pregnancy stages: a cohort study.母亲感染新冠病毒对不同孕期子代免疫及母胎结局的影响:一项队列研究
BMC Pregnancy Childbirth. 2025 Feb 28;25(1):219. doi: 10.1186/s12884-025-07323-7.
2
From intramuscular to nasal: unleashing the potential of nasal spray vaccines against coronavirus disease 2019.从肌肉注射到鼻腔给药:释放鼻喷式疫苗对抗2019冠状病毒病的潜力。
Clin Transl Immunology. 2024 May 20;13(5):e1514. doi: 10.1002/cti2.1514. eCollection 2024.
3
Global prevalence of coronavirus disease 2019 reinfection: a systematic review and meta-analysis.

本文引用的文献

1
On the origin and continuing evolution of SARS-CoV-2.关于严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的起源及持续进化
Natl Sci Rev. 2020 Jun;7(6):1012-1023. doi: 10.1093/nsr/nwaa036. Epub 2020 Mar 3.
2
On the founder effect in COVID-19 outbreaks: how many infected travelers may have started them all?关于新冠疫情中的奠基者效应:究竟有多少受感染的旅行者可能引发了所有这些疫情?
Natl Sci Rev. 2020 Sep 24;8(1):nwaa246. doi: 10.1093/nsr/nwaa246. eCollection 2021 Jan.
3
Pathological changes in the lungs and lymphatic organs of 12 COVID-19 autopsy cases.
全球 2019 冠状病毒病再感染的流行率:系统评价和荟萃分析。
BMC Public Health. 2023 Apr 28;23(1):778. doi: 10.1186/s12889-023-15626-7.
4
Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications.中和抗体对 SARS-CoV-2 感染的保护作用和保护机制及其潜在的临床意义。
Front Immunol. 2023 Jan 19;14:1055457. doi: 10.3389/fimmu.2023.1055457. eCollection 2023.
5
SARS-CoV-2 Omicron (B.1.1.529) Infection of Wild White-Tailed Deer in New York City.SARS-CoV-2 奥密克戎(B.1.1.529)感染纽约市的野生白尾鹿。
Viruses. 2022 Dec 12;14(12):2770. doi: 10.3390/v14122770.
6
Kinetics of severe acute respiratory syndrome coronavirus 2 infection antibody responses.严重急性呼吸综合征冠状病毒 2 感染抗体反应的动力学。
Front Immunol. 2022 Aug 5;13:864278. doi: 10.3389/fimmu.2022.864278. eCollection 2022.
7
Multiple SARS-CoV-2 Reinfections: A Case Series of Thrice-Infected Individuals.新型冠状病毒2型多次重复感染:三重重症感染病例系列
Mayo Clin Proc. 2022 May;97(5):1021-1023. doi: 10.1016/j.mayocp.2022.03.003. Epub 2022 Mar 11.
8
COVID-19 reinfection in Liberia: Implication for improving disease surveillance.利比里亚的 COVID-19 再感染:对改善疾病监测的启示。
PLoS One. 2022 Mar 24;17(3):e0265768. doi: 10.1371/journal.pone.0265768. eCollection 2022.
9
Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection.临床病程对感染后 1 年以上的 SARS-CoV-2 中和抗体的早期动力学、幅度和振幅有影响。
Cell Rep Med. 2022 Jan 24;3(2):100523. doi: 10.1016/j.xcrm.2022.100523. eCollection 2022 Feb 15.
10
Fighting SARS-CoV-2 with green seaweed sp. extract: extraction protocol predetermines crude ulvan extract anti-SARS-CoV-2 inhibition properties in Vero-E6 cells assay.用绿藻提取物对抗严重急性呼吸综合征冠状病毒2:提取方案预先决定了粗制岩藻聚糖硫酸酯提取物在Vero-E6细胞试验中的抗严重急性呼吸综合征冠状病毒2抑制特性。
PeerJ. 2021 Nov 15;9:e12398. doi: 10.7717/peerj.12398. eCollection 2021.
12例新冠病毒病尸检病例肺部及淋巴器官的病理变化
Natl Sci Rev. 2020 Sep 29;7(12):1868-1878. doi: 10.1093/nsr/nwaa247. eCollection 2020 Dec.
4
MINERVA: A Facile Strategy for SARS-CoV-2 Whole-Genome Deep Sequencing of Clinical Samples.MINERVA:一种用于对临床样本进行 SARS-CoV-2 全基因组深度测序的简便策略。
Mol Cell. 2020 Dec 17;80(6):1123-1134.e4. doi: 10.1016/j.molcel.2020.11.030. Epub 2020 Nov 20.
5
Genomic surveillance of COVID-19 cases in Beijing.北京新冠病例的基因组监测。
Nat Commun. 2020 Oct 30;11(1):5503. doi: 10.1038/s41467-020-19345-0.
6
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.针对 SARS-CoV-2 感染的强大中和抗体可长期存在。
Science. 2020 Dec 4;370(6521):1227-1230. doi: 10.1126/science.abd7728. Epub 2020 Oct 28.
7
Genomic evidence for reinfection with SARS-CoV-2: a case study.基因组证据表明 SARS-CoV-2 再次感染:一项案例研究。
Lancet Infect Dis. 2021 Jan;21(1):52-58. doi: 10.1016/S1473-3099(20)30764-7. Epub 2020 Oct 12.
8
The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity.SARS-CoV-2 刺突突变对病毒感染力和抗原性的影响。
Cell. 2020 Sep 3;182(5):1284-1294.e9. doi: 10.1016/j.cell.2020.07.012. Epub 2020 Jul 17.
9
Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19.轻度新冠肺炎患者体内抗SARS-CoV-2抗体的快速衰减
N Engl J Med. 2020 Sep 10;383(11):1085-1087. doi: 10.1056/NEJMc2025179. Epub 2020 Jul 21.
10
Is novel coronavirus 2019 reinfection possible? Interpreting dynamic SARS-CoV-2 test results.新型冠状病毒 2019 年是否可能再次感染?解读动态 SARS-CoV-2 检测结果。
Am J Emerg Med. 2021 Jan;39:256.e1-256.e3. doi: 10.1016/j.ajem.2020.06.079. Epub 2020 Jul 4.